Key result
Intensively treated patients with coexisting systolic heart failure and diabetes showed no significant difference in flow-mediated vasodilatation and intima-media thickness versus healthy controls.
Why the study?
Does intensive medical therapy normalize flow-mediated vasodilatation and intima-media thickness in patients with coexisting systolic heart failure and diabetes compared to healthy controls?
Case-Control (n=45)
Does intensive medical therapy normalize flow-mediated vasodilatation and intima-media thickness in patients with coexisting systolic heart failure and diabetes compared to healthy controls?
Intensively treated patients with coexisting systolic heart failure and diabetes exhibit normal endothelial function and no signs of accelerated atherosclerosis compared to healthy controls.
Answers are grounded in this paper and cite their sources.
Intensive therapy may normalize endothelial function in systolic HF with diabetes; leaves open outcome benefits and needs prospective trials.
OBJECTIVE: Intensive medical treatment of heart failure (HF) patients with diabetes may reduce the endothelial dysfunction and the accelerated atherosclerotic process seen in these patients. To study this, we investigated the endothelial function and the presence of atherosclerosis as measured by flow-mediated vasodilatation (FMD) and intima-media thickness (IMT) in intensively treated patients with coexisting HF and diabetes. RESEARCH DESIGN AND METHOD: FMD of the brachial artery and IMT of the common carotid arteries were determined in 26 patients with systolic HF and diabetes who were in intensive medical therapy, as well as in 19 healthy controls. The two groups were matched according to age and sex. In all subjects left ventricular ejection fraction was measured by two-dimensional echocardiography. Biochemical parameters including serum cholesterol, HDL and LDL, triglyceride, glucose, hemoglobin/hemoglobin-A1C (HbA1C), brain natriuretic peptide (BNP) and N-terminal pro-BNP were also assessed. RESULTS: Mean FMD and IMT did not differ significantly between patients and controls. Left ventricular ejection fraction was lower in patients compared to controls (P < 0.001). The patients had a higher mean BNP, NT pro-BNP, triglyceride, HbA1C and glucose in comparison to controls. Cholesterol, HDL-cholesterol and LDL-cholesterol were lower in patients compared to controls. CONCLUSIONS: Intensively treated patients with coexisting systolic HF and diabetes seem to have normal endothelial function as measured by FMD and they have no sign of accelerated atherosclerosis as measured by IMT. This suggests a positive effect of medication on the cardiovascular alterations in this group of patients.
No takes yet. Share an insight, caveat, or question.
Andersen et al. (2011) conducted a case-control in Coexisting systolic heart failure and diabetes (n=45). Intensive medical therapy vs. Healthy controls was evaluated on Flow-mediated vasodilatation (FMD) and intima-media thickness (IMT). Intensively treated patients with coexisting systolic heart failure and diabetes showed no significant difference in flow-mediated vasodilatation and intima-media thickness versus healthy controls.
Synapse has enriched 10 related papers. Consider them for comparative context: